Important Safety Information
Prescribing Information
Patient Support
Visit Our Patient Site
View Important Safety Information

IMPORTANT SAFETY INFORMATION:

Collapse Important Safety Information
Expand Important Safety Information

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Do not prescribe Sucraid® to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

Prescribing Information DownloadPatient Websites HCP Websites menu

Visit Patient Site

View Important Safety Information

IMPORTANT SAFETY INFORMATION:

Could It Be CSID?

Disease • Diagnosis • Trial Rx

Find Out About a Sucraid® 4-Day Trial

Disease

What is Congenital Sucrase-Isomaltase Deficiency?

Congenital Sucrase-Isomaltase Deficiency (CSID) is a rare disorder caused by variants of the sucrase-isomaltase (SI) gene that code for dysfunctional forms of the enzyme. SI digests sucrose and maltose to enable absorption. Failure to absorb either causes postprandial colonic fermentation and osmotic diarrhea. Children with CSID face unique challenges to their growth and development. When a patient presents with chronic diarrhea, excess flatulence, bloating, and abdominal pain, it could be CSID.

Learn from Our Experts that Treat CSID with Sucraid®

Play podcast
Play podcast
Play podcast
Play podcast
Play podcast
Play podcast

Diagnosis

How to Diagnose CSID

CSID is largely a clinical diagnosis.

Disaccharidase Assay

A disaccharidase assay using the substrate sucrose can detect deficient sucrase activity when it occurs in EGD-biopsied tissue.

Sucrose Breath Tests

Breath tests (hydrogen-methane and 13C-sucrose) quantify the ability to digest sucrose by measuring the metabolic products of sucrose digestion in exhaled air.

4-4-4 Simple Oral Sugar (Sucrose) Challenge

A qualitative assessment of the ability to digest sugar can be made by observing, over a 4-hour period, the GI response to drinking a solution of 4 tablespoons of sugar dissolved in 4 ounces of water. Individuals with CSID may experience severe GI symptoms. Thus, this test is not appropriate for infants, young children, diabetics, or the elderly.

Therapeutic Response Trial

Candidates for a brief therapeutic trial of sacrosidase, enzyme replacement for sucrase, include GI patients suspected of CSID who are not eligible for an EGD to obtain tissue for disaccharidase assay, or those with a suspected but unconfirmed diagnosis of CSID. Patients with CSID should experience significant relief of GI symptoms when taking sacrosidase. Sacrosidase is contraindicated in patients known to be hypersensitive to yeast, yeast products, glycerin (glycerol), or papain.

Unless combined with a clinical history of chronic, postprandial GI symptoms and/or normal small bowel histology, none of these diagnostic tests, which detect sucrase deficiency, are able to differentiate between primary sucrase deficiency, which is a part of CSID, and secondary or acquired sucrase deficiency.

Trial Rx

Download a 4-Day Trial Rx Form

Sucraid® 4-Day Trial (4DT) offers eligible patients a short therapeutic trial of Sucraid® (sacrosidase) Oral Solution to assess response in patients suspected of having congenital sucrase-isomaltase deficiency (CSID) to help confirm a CSID diagnosis.

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Do not prescribe Sucraid® to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.